Reaction profile
The FDA adverse-event record for product problem
10,340 FDA reports name product problem, a high-volume reaction in the CVM extract (VeDDRA 2283). Plate stamps and neighbourhood peers follow.
- #44 of 2,481
- by report volume (all reactions)
- 10,340
- reports citing this reaction
- 0.3%
- death-coded share
- Unknown
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Product problem has 10,340 reports now versus 10,340 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- −0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Product problem changesFDA AER · VeDDRA plate
Code 2283 VOL-HIGH
VOL-HIGH · DEATH-RARE · TOP-DECILE · PHOTO-FINISH · SPECIES-UNKNOWN · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-HIGH 10,340 reports
- DEATH-RARE 0.3%
- TOP-DECILE #44/2481
- PHOTO-FINISH Uncoded sign
- SPECIES-UNKNOWN Unknown · 9,489
- DRUG-LEAD Milbemycin Oxime… · 2,624
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Uncoded sign (±161 reports)
Upper-third report volume drives the scale stamps on this plate; death-coded share and co-report peers follow. Not a clinical diagnosis.
High-volume neighbourhood around Product problem
Upper-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Product problem: low death-coded share in the FDA AER plate
Signature read: 10,340 reports place Product problem in the upper third of FDA AER volume (#44 of 2,481). Report volume is upper-third scale: 10,340 named reports in the openFDA extract. Death-coded share is lower-third: 32 of 10,340 reports (0.3% of named reports). Nearest volume peer: Uncoded sign (±161 reports). Lead species Unknown (9,489). Lead co-reported drug Milbemycin Oxime + Spinosad (2,624).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Milbemycin Oxime + Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Product problem, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (10,340 here).
Similar death-coded share
Nearest other reactions by death-coded share (0.3% here), distinct from the volume row.
What to do with this reaction
- Compare Product problem's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →